Research Article
Comparative Efficacy Study Combination of Oral Methotrexate and Prednisolone versus Oral Methotrexate in Patients with Lichen Planopilaris
Table 6
Comparison of sign and symptoms between combined and methotrexate therapy at the baseline and within the follow-up.
| | Baseline | Two months after intervention | Four months after intervention | Six months after intervention | MTX | COM | | MTX | COM | | MTX | COM | | MTX | COM | |
| Pain, n (%) | No | 10 (71.43) | 8 (57.14) | 0.745 | 11 (91.67) | 11 (91.67) | 0.999 | 11 (91.67) | 12 (100) | — | 12 (100.0) | 12 (100.0) | — | Mild | 3 (21.43) | 4 (28.57) | 0 (0) | 1 (8.33) | 1 (8.33) | 0 (0) | 0 (0) | 0 (0) | Moderate | 1 (7.14) | 2 (14.29) | 1 (8.33) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Severe | 0 (0) | 0 (0) | | 0(0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Pruritus, n (%) | No | 2 (14.29) | 2 (14.29) | 0.877 | 4 (33.33) | 6 (50) | 0.663 | 5 (41.67) | 10 (83.33) | 0.115 | 6 (50) | 10 (83.33) | 0.244 | Mild | 2 (14.29) | 4 (28.57) | 5 (41.67) | 5 (41.67) | 5 (41.67) | 2 (16.67) | 4 (33.33) | 2 (16.67) | Moderate | 4 (28.57) | 4 (28.57) | 3 (25) | 1 (8.33) | 1 (8.33) | 0 (0) | 2 (16.67) | 0 (0) | Severe | 6 (42.86) | 4 (28.57) | 0 (0) | 0 (0) | 1 (8.33) | 0 (0) | 0 (0) | 0 (0) | Soreness, n (%) | No | 8 (57.14) | 8 (57.4) | 0.745 | 10 (83.33) | 9 (75.00) | 0.50 | 9 (75.00) | 12 (100.00) | 0.217 | 11 (91.67) | 12 (100) | 0.50 | Mild | 5 (35.71) | 3 (21.43) | 2 (16.67) | 3 (25.0) | 2 (16.67) | 0 (0) | 1 (8.33) | 0 (0) | Moderate | 1 (7.14) | 2 (14.29) | 0 (0) | 0 (0) | 1 (8.33) | 0 (0) | 0 (0) | 0 (0) | Severe | 0 (0) | 1 (7.14) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Erythema, n (%) | No | 5 (35.71) | 3 (21.43) | 0.580 | 6 (50) | 4 (33.33) | 0.236 | 6 (50) | 7 (58.33) | 0.999 | 10 (83.33) | 10 (83.33) | 0.999 | Mild | 4 (28.57) | 2 (14.29) | 5 (41.67) | 3 (25) | 5 (41.67) | 4 (33.33) | 0 (0) | 1 (8.33) | Moderate | 4 (28.57) | 6 (42.86) | 1 (8.33) | 5 (41.67) | 1 (8.33) | 1 (8.33) | 2 (16.67) | 1 (8.33) | Severe | 1 (7.14) | 3 (21.43) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Perifollicular erythema, n (%) | No | 1 (7.14) | 0 (0) | 0.707 | 1 (8.33) | 2 (16.67) | 0.043 | 7 (58.33) | 7 (58.33) | 0.418 | 5 (41.67) | 7 (58.33) | 0.684 | Mild | 5 (35.71) | 6 (42.86) | 10 (83.33) | 4 (33.33) | 5 (41.67) | 3 (25) | 6 (50) | 5 (41.67) | Moderate | 5 (35.71) | 3 (21.43) | 0 (0) | 4 (33.33) | 0 (0) | 2 (16.67) | 1 (8.33) | 0 (0) | Severe | 3 (21.43) | 5 (35.71) | 1 (8.33) | 2 (16.67) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Perifollicular scaling, n (%) | No | 2 (14.29) | 4 (28.57) | 0.766 | 2 (16.67) | 3 (25) | 0.067 | 5 (41.67) | 3 (25) | 0.528 | 2 (16.67) | 3 (25) | 0.564 | Mild | 7 (50) | 4 (28.57) | 7 (58.33) | 2 (16.67) | 4 (33.33) | 2 (16.67) | 5 (41.67) | 2 (16.67) | Moderate | 3 (21.43) | 4 (28.57) | 1 (8.33) | 6 (50) | 2 (16.67) | 4 (33.33) | 4 (33.33) | 4 (33.33) | Severe | 2 (14.29) | 2 (14.29) | 2 (16.67) | 1 (8.33) | 1 (8.33) | 3 (25) | 1 (8.33) | 3 (25) | Pull test, n (%) | No | 8 (57.14) | 9 (64.29) | 0.50 | 12 (100) | 12 (100) | — | 12 (100) | 12 (100) | — | 12 (100) | 12 (100) | — | Presence | 6 (42.86) | 5 (35.71) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Spreading, n (%) | No | 0 (0) | 8 (57.14) | <0.001 | 8 (66.67) | 9 (75) | 0.202 | 9 (75) | 12 (100) | 0.217 | 10 (83.33) | 12 (100) | 0.478 | Intermediate | 1 (7.14) | 3 (21.43) | 1 (8.33) | 3 (25) | 1 (8.33) | 0 (0) | 2 (16.67) | 0 (0) | Presence | 13 (92.86) | 3 (21.43) | 3 (25) | 0 (0) | 2 (16.67) | 0 (0) | 0 (0) | 0 (0) | Follicular keratosis, n (%) | No | 0 (0) | 0 (0) | 0.162 | 0 (0) | 0 (0) | 0.648 | 0 (0) | 0 (0) | 0.158 | 1 (8.33) | 1 (8.33) | 0.784 | Mild | 4 (28.57) | 7 (50) | 8 (66.67) | 6 (50) | 8 (66.67) | 11 (91.67) | 8 (66.67) | 10 (83.33) | Moderate | 7 (50) | 2 (14.29) | 3 (25) | 3 (25) | 4 (33.33) | 1 (8.33) | 3 (25) | 1 (8.33) | Severe | 3 (21.43) | 5 (35.71) | 1 (8.33) | 3 (25) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
|
|
MTX: methotrexate; COM: combined therapy.
|